Director Jonathan Schechter buys 60,000 PharmaCyte (PMCB) shares

Rhea-AI Filing Summary

PharmaCyte Biotech director buys additional shares

Director Jonathan Schechter reported buying a total of 60,000 shares of PharmaCyte Biotech, Inc. common stock in the open market over three consecutive days. He purchased 20,000 shares on January 5, 2026 at $0.7776 per share, 20,000 shares on January 6, 2026 at $0.7904 per share, and 20,000 shares on January 7, 2026 at $0.8436 per share. Following these transactions, Schechter directly owned 192,500 shares of PharmaCyte common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SCHECHTER JONATHAN

(Last) (First) (Middle)

C/O PHARMACYTE BIOTECH, INC.

3960 HOWARD HUGHES PARKWAY, SUITE 500

(Street)

LAS VEGAS NV 89169

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PharmaCyte Biotech, Inc. [ PMCB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/05/2026		P		20,000	A	$0.7776	152,500	D
Common Stock	01/06/2026		P		20,000	A	$0.7904	172,500	D
Common Stock	01/07/2026		P		20,000	A	$0.8436	192,500	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Jonathan Schechter	01/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who is the insider trading PharmaCyte Biotech (PMCB) shares in this Form 4?

The Form 4 identifies Jonathan Schechter as the reporting person. He is a director of PharmaCyte Biotech, Inc. and is not listed as an officer or 10% owner in this filing.

Did the PharmaCyte Biotech (PMCB) insider buy or sell shares?

The insider activity consists of purchases of common stock. Transaction code "P" indicates open-market or private purchase transactions, and all three reported trades are coded as purchases.

How many PharmaCyte Biotech (PMCB) shares did Jonathan Schechter purchase?

Jonathan Schechter purchased 60,000 shares of PharmaCyte Biotech common stock in total, in three separate transactions of 20,000 shares each on January 5, 6, and 7, 2026.

At what prices were the PharmaCyte Biotech (PMCB) shares bought in this Form 4?

The reported purchase prices were $0.7776 per share on January 5, 2026, $0.7904 per share on January 6, 2026, and $0.8436 per share on January 7, 2026.

How many PharmaCyte Biotech (PMCB) shares does Jonathan Schechter own after these transactions?

After the reported purchases, Jonathan Schechter beneficially owned 192,500 shares of PharmaCyte Biotech common stock, held in direct ownership according to the filing.

Were any derivative securities reported for PharmaCyte Biotech (PMCB) in this Form 4?

The section for derivative securities is present, but no derivative transactions or holdings are listed. All reported activity relates to non-derivative common stock.

Is this PharmaCyte Biotech (PMCB) Form 4 filed for one insider or multiple insiders?

The document indicates it is a Form filed by one reporting person, covering only director Jonathan Schechter. No additional reporting persons are included.